위궤양환자에서 Rebamipide ( MUCOSTAR ) 의 치료 효과

Baekground: H2, blockers have been the first drug of choice in the non-surgical cares of peptic ulcer patients, but have raised the clinical problem of recurrence promptly following discontinuation of use . One of the arguments concerning recurrence refers to the drastic suppression of aggressive factors, probably deteriorating the defence factors. Extensive research have been conducted to accumulate the knowledge on the defense mechanism of the gastric. mucosa in order to advocate the use of H - blockers in the treatment of gastric uIcer. Rebamipide is a novel antiulcer agent that enhances the mucosal defensive mechanism by increasing the generation of endogenous prostaglandins which controls the overall defensive mechanism. Methods: To evaluate the effect of Rebamipide on the gastric ulcer disease, Rebamipide(MUCOSTA ) was orally daministered 100 mg three times a day for 8 weeks to 30 patients with benign active gastric ulcer disease. Results: Subjective symptorns were remarkably improved in 66.7% of the subjects. Active stage of gastric ulcer were remarkably improved in 70% of the subjects. General improvement rate was remarkable 70.0% and effectiveness rate of Rebamipide was 83.3% after 8 weeks of treatment. No significant clinical side effects had been noticed. Conclusion: These results indicate that oral administration of Rebamipide is effective and safe treatment of gastric ulcer disease. But for the higher healing rate, more long term treatment of Rebamipide should be considered.